SAN CARLOS, Calif., Nov. 9, 2016 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, today reported financial results for the third quarter ended September 30, 2016 and provided an update on recent business progress.
Recent Accomplishments & Highlights
Generated total revenues of $53.9 million in the third quarter of 2016 compared to $44.9 million in the third quarter of 2015, an increase of 20%
Accessioned greater than 109,000 tests in the third quarter of 2016 compared to approximately 84,000 tests accessioned in the third quarter of 2015, an increase of approximately 30%
Accessioned greater than 84,000 Panorama tests in the third quarter of 2016 compared to approximately 67,000 tests accessioned in the third quarter of 2015, an increase of approximately 25%
Accessioned greater than 20,000 Horizon carrier screening tests in the third quarter of 2016 compared to approximately 13,000 Horizon carrier screening tests accessioned in the third quarter of 2015, an increase of approximately 54%
Medical coverage policies that include coverage for average risk NIPT have now expanded to plans representing over 90 million covered lives in the United States, including a recent positive coverage decision from Cigna
The first peer-reviewed clinical trial providing evidence that primary obstetrical care providers can effectively offer cfDNA aneuploidy screening to the general population as part of routine clinical practice has been accepted for publication in Genetics and Medicine. The study was led by Glenn Palomaki of Brown University and featured the use of Panorama
The National Society of Genetic Counselors issued an updated position statement on cell free DNA screening endorsing NIPT as an option for all pregnant patients
Recent Accomplishments & Highlights
Generated total revenues of $53.9 million in the third quarter of 2016 compared to $44.9 million in the third quarter of 2015, an increase of 20%
Accessioned greater than 109,000 tests in the third quarter of 2016 compared to approximately 84,000 tests accessioned in the third quarter of 2015, an increase of approximately 30%
Accessioned greater than 84,000 Panorama tests in the third quarter of 2016 compared to approximately 67,000 tests accessioned in the third quarter of 2015, an increase of approximately 25%
Accessioned greater than 20,000 Horizon carrier screening tests in the third quarter of 2016 compared to approximately 13,000 Horizon carrier screening tests accessioned in the third quarter of 2015, an increase of approximately 54%
Medical coverage policies that include coverage for average risk NIPT have now expanded to plans representing over 90 million covered lives in the United States, including a recent positive coverage decision from Cigna
The first peer-reviewed clinical trial providing evidence that primary obstetrical care providers can effectively offer cfDNA aneuploidy screening to the general population as part of routine clinical practice has been accepted for publication in Genetics and Medicine. The study was led by Glenn Palomaki of Brown University and featured the use of Panorama
The National Society of Genetic Counselors issued an updated position statement on cell free DNA screening endorsing NIPT as an option for all pregnant patients
